open access
Botulinum toxin type A for hand tremor: a meta-analysis of randomised controlled trials
Affiliations- Guangzhou University of Traditonal Chinese Medicine, No 12，Baiyun District, 510000 Guangzhou, China
open access
Abstract
Background. Tremor is one of the most common movement disorders. It does not usually respond to first-line drug treatments (e.g. propranolol, primidone, anticholinergics, gabapentin and clonazepam) due to side effects and frequent dose limitations. Botulinum toxin type A (BoNT-A) has been widely used to treat tremor, but its efficacy and safety are uncertain.
Aims. To evaluate the efficacy and safety of BoNT-A in the treatment of hand tremor.
Methods. We searched the MEDLINE, EMBASE, PsycINFO and Cochrane Library databases for relevant randomised controlled trials of the effects of BoNT-A injections on tremors, up to 20 February 2020. A meta-analysis of comparative effects was performed using R studio software, and publication bias was examined using Egger’s test.
Results. Six studies examining a total of 245 participants with tremor were included in the meta-analysis. The primary outcome of meta-analysis showed no difference in clinical tremor scale scores between the BoNT-A group versus the placebo group (standardised mean difference (SMD): -0.42, 95% confidence interval (CI): -1.94 to 1.10; I2 = 96%). For clinical tremor scale scores, subgroup analyses suggested that the BoNT-A group may differ in terms of multiple sclerosis (MS) related tremor (SMD: -1.10; 95% CI: -2.17 to -0.04; I2 = 79%) compared to a placebo, but the difference did not exist in the outcome of essential tremor (ET) or hand tremor (MD: -1.31; 95% CI: -3.39; 1.31; I2 = 97%). Grip strength (MD: -1.25, 95% CI: -5.99 to 3.50, I2 = 97%) was slightly lower in the BoNT-A group, but the difference was not significant. The incidence of adverse events (AEs), including hand weakness (RR: 2.96, 95% CI: 1.40 to 6.24, I2 = 37%), was significantly greater in the BoNT-A group than in the placebo group. Two studies were assessed as having an overall low risk of bias.
Conclusions. Our study confirms that BoNT-A injections are unlikely to have an impact on patients with hand tremors. However, subgroup analysis suggested that BoNT-A injections could have possible benefits in MS-related tremor. While moderate to severe hand weakness AEs often limits their use in clinical practice, additional well-designed double-blind, placebo-controlled trials are needed to provide more robust conclusions.
Abstract
Background. Tremor is one of the most common movement disorders. It does not usually respond to first-line drug treatments (e.g. propranolol, primidone, anticholinergics, gabapentin and clonazepam) due to side effects and frequent dose limitations. Botulinum toxin type A (BoNT-A) has been widely used to treat tremor, but its efficacy and safety are uncertain.
Aims. To evaluate the efficacy and safety of BoNT-A in the treatment of hand tremor.
Methods. We searched the MEDLINE, EMBASE, PsycINFO and Cochrane Library databases for relevant randomised controlled trials of the effects of BoNT-A injections on tremors, up to 20 February 2020. A meta-analysis of comparative effects was performed using R studio software, and publication bias was examined using Egger’s test.
Results. Six studies examining a total of 245 participants with tremor were included in the meta-analysis. The primary outcome of meta-analysis showed no difference in clinical tremor scale scores between the BoNT-A group versus the placebo group (standardised mean difference (SMD): -0.42, 95% confidence interval (CI): -1.94 to 1.10; I2 = 96%). For clinical tremor scale scores, subgroup analyses suggested that the BoNT-A group may differ in terms of multiple sclerosis (MS) related tremor (SMD: -1.10; 95% CI: -2.17 to -0.04; I2 = 79%) compared to a placebo, but the difference did not exist in the outcome of essential tremor (ET) or hand tremor (MD: -1.31; 95% CI: -3.39; 1.31; I2 = 97%). Grip strength (MD: -1.25, 95% CI: -5.99 to 3.50, I2 = 97%) was slightly lower in the BoNT-A group, but the difference was not significant. The incidence of adverse events (AEs), including hand weakness (RR: 2.96, 95% CI: 1.40 to 6.24, I2 = 37%), was significantly greater in the BoNT-A group than in the placebo group. Two studies were assessed as having an overall low risk of bias.
Conclusions. Our study confirms that BoNT-A injections are unlikely to have an impact on patients with hand tremors. However, subgroup analysis suggested that BoNT-A injections could have possible benefits in MS-related tremor. While moderate to severe hand weakness AEs often limits their use in clinical practice, additional well-designed double-blind, placebo-controlled trials are needed to provide more robust conclusions.
Keywords
systematic review, meta-analysis, botulinum toxin, tremor
Supp./Additional Files (7)
About this articleTitle
Botulinum toxin type A for hand tremor: a meta-analysis of randomised controlled trials
Journal
Neurologia i Neurochirurgia Polska
Issue
Article type
Research Paper
Pages
561-567
Published online
2020-10-12
Page views
1432
Article views/downloads
1307
DOI
Pubmed
Bibliographic record
Neurol Neurochir Pol 2020;54(6):561-567.
Keywords
systematic review
meta-analysis
botulinum toxin
tremor
Authors
Xiaoyan Zheng
Wenjing Wei
Peidong Liu
Chunxiao Wu
Liming Lu
Chunzhi Tang
References (24)- Elias WJ, Shah BB. Tremor. JAMA. 2014; 311(9): 948–954.
- Liu HC, Wang SJ, Fuh JL, et al. The Kinmen Neurological Disorders Survey (KINDS): A Study of a Chinese Population. Neuroepidemiology. 1997; 16(2): 60–68.
- Larsson T. Sjogren T, Essential tremor: a clinical and genetic population study. Acta Psychiatr Scand Suppl, 1960. 36(144): p. : 1–176.
- Louis ED, Ferreira JJ. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord. 2010; 25(5): 534–541.
- Pringsheim, T., , The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord, 2014. 29(13): p. : 1583–90.
- Labiano-Fontcuberta A, Benito-León J. Understanding Tremor in Multiple Sclerosis: Prevalence, Pathological Anatomy, and Pharmacological and Surgical Approaches to Treatment. Tremor and Other Hyperkinetic Movements. 2012; 2(0): 02.
- Lyons KE, Pahwa R. Pharmacotherapy of essential tremor : an overview of existing and upcoming agents. CNS Drugs. 2008; 22(12): 1037–1045.
- Baizabal-Carvallo JF, Jankovic J. Movement disorders induced by deep brain stimulation. Parkinsonism Relat Disord. 2016; 25: 1–9.
- Schneider SA, Deuschl G. The treatment of tremor. Neurotherapeutics. 2014; 11(1): 128–138.
- Koller WC, Vetere-Overfield B. Acute and chronic effects of propranolol and primidone in essential tremor. Neurology. 1989; 39(12): 1587–1588.
- Wasielewski PG, Burns JM, Koller WC. Pharmacologic treatment of tremor. Mov Disord. 1998; 13 Suppl 3: 90–100.
- Atuah, K.N., D. Hughes and M. Pirmohamed, Clinical pharmacology: special safety considerations in drug development and pharmacovigilance. Drug Saf, 2004. 27(8): p. : 535–54.
- Niemann N, Jankovic J. Botulinum Toxin for the Treatment of Hand Tremor. Toxins (Basel). 2018; 10(7).
- Savović J, Weeks L, Sterne JAC, et al. Evaluation of the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation. Syst Rev. 2014; 3: 37.
- Brin MF, Lyons KE, Doucette J, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001; 56(11): 1523–1528.
- Jankovic J, Schwartz K, Clemence W, et al. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996; 11(3): 250–256.
- Mittal S, Machado D, Richardson D, et al. Botulinum Toxin in Parkinson Disease Tremor. Mayo Clinic Proceedings. 2017; 92(9): 1359–1367.
- Van Der Walt A, Sung S, Spelman T, et al. A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor. Neurology. 2012; 79(1): 92–99.
- Mittal SOm, Machado D, Richardson D, et al. Botulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach. Parkinsonism Relat Disord. 2018; 56: 65–69.
- Boonstra FMC, Evans A, Noffs G, et al. OnabotulinumtoxinA treatment for MS-tremor modifies fMRI tremor response in central sensory-motor integration areas. Mult Scler Relat Disord. 2020; 40: 101984.
- Ferreira J, Costa J, Coelho M, et al. The management of cervical dystonia. Expert Opinion on Pharmacotherapy. 2007; 8(2): 129–140.
- Zakin E, Simpson D. Botulinum Toxin in Management of Limb Tremor. Toxins (Basel). 2017; 9(11).
- Safarpour Y, Jabbari B. Botulinum Toxin Treatment of Movement Disorders. Curr Treat Options Neurol. 2018; 20(2): 4.
- Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008; 336(7644): 601–605.
